Company: ANIX
Filing Date: 2025-01-10
Form Type: S-8
Source: 0001493152-25-001798
Chunk: 2

Company: Anixa Biosciences Inc
Filing Date: 2025-01-10
Form: S-8
Chunk 2
---
 be offered and sold pursuant to the 2018 Share Incentive Plan (the “2018 Plan”) in connection with an increase in the number of shares available for issuance under such plan in 2025 pursuant to the evergreen provision included therein and to file a prospectus, prepared in accordance with the requirements of Part I of Form S-3 and, pursuant to General Instruction C of Form S-8, to be used for reoffers and resales of Common Stock acquired by persons to be named therein upon the exercise of options and restricted stock awards granted under the 2018 Plan, the 2010 Share Incentive Plan, as amended (the “2010 Plan”) and the purchase of shares pursuant to our Employee Stock Purchase Plan (the “ESPP”).

Pursuant to the Note to Part I on Form S-8, the documents containing the information specified in Part I of this Registration Statement will be sent or given to plan participants (including to all employees eligible to participate in the ESPP) as specified by Rule 428(b)(1) of the Securities Act. Such documents are not required to be filed, and are not filed, with the United States Securities and Exchange Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

| iii |

<div align='center'>REOFFER PROSPECTUS

Anixa Biosciences, Inc.

Up to 13,435,835 shares of Common Stock under the 2018 Share Incentive Plan, Employee Stock Purchase Plan and the 2010 Share Incentive Plan, as amended</div>

This prospectus relates to the resale of up to 13,435,835 shares (the “Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of Anixa Biosciences, Inc., a Delaware corporation (the “Company”, “us”, “our” or “we”), which may be offered and sold from time to time by certain stockholders of the Company (the “Selling Stockholders”) who have acquired or will acquire such Shares in connection with the exercise of stock options granted, and with stock or other awards made, and with the purchase of stock under, the